Association of clinicopathological variables with TAMs and Cox-2 in canine melanocytic tumours.
1. Introduction
Melanoma is a devastating disease frequently encountered within both veterinary and human medicine. Melanocytic tumours are relatively common in dogs and represent 4 to 7% of all canine neoplasms. It is the most common malignant neoplasm of the oral cavity and the second most frequent subungual neoplasm. Classically, body location is one criteria used to establish a prognosis of these tumours (Martínez et al., 2011; Smith et al., 2002). Cutaneous canine melanocytic lesions are usually benign. However, the canine oropharyngeal, uveal, and mucocutaneous neoplasms are aggressive and have high metastatic potential (Marino et al., 1995; Smith et al., 2002; Spangler & Kass, 2006).
In other animals species melanocytic tumours were also seen, but in cats it is not as common and carries a poor prognosis (Dorn&Priester, 1976; Goldschmidt, 1985). In white or gray horses melanoma is very common, considered almost inevitable (Johnson, 1998; Valentine, 1995). In pigs, melanoma is very frequent in some breeds, as Sinclair (Berkelhammer&Hook, 1980; Hook et al., 1982; Misfeldt & Grimm, 1994).
Generally, cutaneous melanoma in domestic animals does not share the same degree of diversity described in the medical literature. Canine cutaneous melanoma can be either benign (melanocytoma) or malignant (melanoma) and are most common in older animals with darker coats. The benign form is often referred to as melanocytic nevus or melanocytoma, and is well-defined, firm, dome-shaped, with less than 2 cm in diameter and mobile. Malignant melanomas are less frequent in the skin and appear ulcerated with a rapid grow. Most oral and mucocutaneous (except eyelid) and 50% of nail bed (subungual) melanomas are malignant (Smith et al., 2002)
Unlike humans, dogs do not seem to develop malignant melanomas due to exposure to ionizing solar radiation. With the exception of gray horses, malignant transformation of benign lesions is very uncommon in animals, and most melanomas are believed to arised “
Cutaneous melanoma is the group of melanocytic lesions that constitute the big challenge to pathologist. The majority of the cases are benign but can be find malignant melanomas with elevated aggressiveness. Mitotic rate is highly predictive of the degree of malignancy and a mitotic rate of less than 3 per 10 high-power fields is strongly associated with benign behavior (Smith et al., 2002). Additional analysis by flow cytometry has shown a correlation between DNA ploidy and malignancy (Bolon et al., 1990). In the last years, several prognostic factors related to proliferation (Laprie et al., 2001; Roels et al., 1999), angiogenesis (Mukaratirwa et al., 2006; Taylor et al., 2007), apoptosis (Roels et al., 2001), and others have been investigated.
The incidence of melanocytic lesions is increasing among canine population. Canine malignant melanoma could have an aggressive behavior, metastasize early in the course of the disease and is resistant to most current therapeutic regimens. The role of a vaccine and the search of novel therapeutic tools are essential in the fight against this devastating disease. Furthermore, the similarities between human and canine melanoma make spontaneous canine melanoma an excellent disease model for studying the correspondent human disease (Bergman et al., 2006; Smith et al., 2002; von Euler et al., 2008).
Inflammation in tumour stroma greatly influences its development. In human cancer it has been described that tumour associated macrophages (TAMs) may promote tumour cell invasiveness and potentiate metastatic diffusion. Among the various inflammatory mediators generated by TAM, assume particular relevance the arachidonic acid metabolites, which are known to influence several biological responses involved in tumour progression, such as inflammatory and immune reactions, haemostasis and angiogenesis. Although the scientific evidence of an association between TAM and histological aggressiveness in human melanoma (Bianchini et al., 2007; Brocker et al., 1987), in the dog there are no studies concerning this subject.
Cyclooxigenase (-1 and -2) are isoenzymes that promote the transition of arachidonic acid in to different prostanoids. These isoenzymes are also the main targets of the NSAIDs (non steroid anti-inflammatory drugs). Several studies have been suggested the potential role of NSAID blocking particularly cyclo-oxygenases-2 (Cox-2) in the prevention and treatment of malignant tumours in humans (Cerella et al., 2010; Dubois et al., 1998). In dogs, there are evidences of a strong relationship between Cox-2 expression and malignancy in several types of cancers (bladder, skin, intestinal, mammary, bone, nasal) (Mohammed et al., 2004; Queiroga et al., 2007). Cox-1 and Cox-2 expression in canine melanocytic lesions has been recently published by the authors, describing that Cox-2 expression was restricted to the malignant melanoma group, being found in 11 of the 20 cutaneous malignant melanomas, in all oral malignant melanomas and in one of two ocular malignant melanomas analyzed. Authors also found that Cox-2 labeling was particularly intense in the more aggressive oral tumours (Pires et al., 2010). In human melanoma, Cox-2 has been implied in tumour progression (Chwirot&Kuzbicki, 2007; Kuzbicki et al., 2006).
The aims of the present work were: a) to describe, the number and the distribution of TAMs in canine melanocytic lesions; b) to investigate associations between TAMs and several clinicopathological characteristics; c) investigate the possible association between Cox-2 expression and the presence of TAMs in these tumours.
2. Material and methods
2.1. Tissue processing and tumour classification
Thirty seven melanocytic tumours, obtained from the UTAD Histopathology Laboratory archives were included. For the histopathologic study, 4-µm-thick tissue sections were stained with the hematoxylin and eosin with and without blanching by incubation in 0,25% potassium permanganate for 30–60 minutes, depending on the amount of pigment and then by incubation in 0,1% oxalic acid for 5–8 minutes. Each sample was re-examined by two independent pathologists (IP and JP) in order to confirm the diagnosis, according to the World Health Organization International Histological Classification of Tumours of Domestic Animals criteria (Goldschmidt et al., 1998).
2.2. Clinicopathological evaluation
The following clinicopathological features were evaluated: histological type-melanocytoma (benign), melanoma (malign); presence of ulceration; presence of necrosis; mitotic index; nuclear grade; degree of pigmentation, presence of aberrant tumoural cells; stroma; and tumoural vascular invasion. Mitotic index was calculated by counting all the mitosis present in 10 high power fields (HPF) (400x): mitotic index I (<3 mitosis in 10 HPF); mitotic index II (3–5 mitosis in 10 HPF) or mitotic index III (>5 mitosis in 10 HPF). For nuclear grade, the following grades were defined: (i) nuclear grade I when the nuclei had minimal variations in their shape and size compared to normal nuclei; (ii) nuclear grade II consisted of moderate alterations of nuclear shape; and (iii) nuclear grade III consisted of the nuclei that were irregular and larger than normal (Queiroga et al., 2010).The degree of pigmentation was estimated using a subjective scale from scant (pigment in fewer than 30% of cells), moderate (pigmentation in 31–80% of cells), and abundant (pigment in more than 80% of cells). The amount of stroma was categorized in: scant, moderate, and abundant (Ramos-Vara et al., 2000).
2.3. Immunohistochemistry
For immunohistochemical studies, 3-µm sections were cut from each specimen and mounted on silane-coated slides. MAC 387 (for macrophage immunolabelling) and Cox-2 immunoexpression were carried out by the streptavidin-biotin-peroxidase complex method, with a commercial detection system (Ultra Vision Detection System; Lab Vision Corporation, Fremont, USA) following the manufacturer’s instructions, with and without blanching. Antigen retrieval was by microwave treatment in citrate buffer (pH 6.0) three times for 5 min each in a 750 W microwave oven, followed by cooling for 20 min at room temperature.
Primary antibodies were: MAC 387 (AbDSerotec, MorphoSys UK Ltd., Kidlington, Oxford,U.K.; Clone MCA 874G) diluted 1 in 100 in PBS and applied for 1 h at room temperature and COX-2 (Transduction Laboratories, Lexington, Kentucky; clone 33) diluted 1 in 40 in phosphate buffered saline (PBS; pH 7.4, 0.01 M) and applied overnight at 4°C.
Immunoreaction was visualized by incubation with 3,3’-diaminobenzidine tetrahydrochloride (DAB) at 0.05% with 0.01% H2O2 as the final substrate for 5 minutes. After a final washing in distilled water, the sections were counterstained with haematoxylin, dehydrated, cleared and mounted.
The primary antibody was replaced by PBS and by an irrelevant antibody for negative controls. Positive controls consisted of canine epidermis and liver for MAC 387 and sections from
2.4. Immunohistochemistry evaluation
Positivity was indicated by the presence of distinct brown cytoplasmic labeling. Immunoreactivity was evaluated ‘‘blindly’’ by two observers (IP e FLQ).
TAMs were counted in the three regions with more intense and homogeneous positivity of each of counting areas (Hussein et al., 2009). In these regions, we counted all labeled cells, evaluating a total of ten high-power fields (HPF), (400x magnification power). TAM were then categorized in three classes: 1: <20 positive macrophages (sparse); 2: 20-100 (moderate), 3: >100 positive macrophages (intense) (Piras et al., 2005).
Positive Cox-2 expression was defined when more than 10% of the tumour cells showed positive staining. The staining intensity was not scored in this method.
2.5. Statistical analysis
The statistical software SPSS version 12.0 was used for statistical analysis. The Chi-square test and the Fisher’s exact test were used for studying categorical variables. In all statistical comparisons, p< 0.05 was accepted as denoting significant differences.
3. Results
3.1. Tumours
From the 37 tumours included in the study, 8 cases were classified as melanocytomas (benign tumours) and 29 cases as malignant melanomas (malignant tumours, Fig.1).
3.2. Tumour- associated macrophages (TAMs) in canine melanocytic tumours
MAC 387 immunostaining was always observed in the cytoplasm of macrophages in a diffuse and homogeneous pattern. The upper layers of epidermis also stained with MAC 387.
TAMs were observed in all the samples analyzed (n=37). As shown in Table 1, all the benign lesions had sparse macrophage infiltration, while malignant melanomas presented a moderate or intense infiltration (Fig.2 and Fig.3). The number of tumoural-associated macrophages in malignant melanoma was significantly higher than the mean values in the benign counterparts (p=0,002).
3.3. Cox-2 expression in canine melanocytic tumours
The expression of COX-2 was absent in 18/37 (48,6%) of the canine melanocytic tumours (Fig. 4). None of the 8 benign tumours expressed Cox-2 in tumoural cells. Among the malignant tumours, COX-2 was expressed by 19 of the 29 melanomas (65,5%), (Fig. 5, Fig. 6). There was a significant difference in COX-2 expression between melanocytomas and malignant melanomas (p < 0,001).
3.4. Association between TAMs and COX-2 and clinicopathological features in canine melanocytic tumours
Table 1 presents the clinicopathological variables analyzed and its association with TAM and Cox-2 expression in canine melanocytic tumours.
The number of TAMs presented a statistical significant association with the presence of ulceration (p<0,001), presence of necrosis (0,001), nuclear grade (p=0,046), degree of pigmentation (p<0,001), tumoural aberrant cells (p=0,014), stroma (p=0,018) and tumoural embolus (p=0,011). Canine melanocytictumours with ulceration, necrosis, with a high nuclear grade, less pigmented, with the presence of tumoural aberrant cells, with a scarce or moderate stroma and with vascular invasion have a high number of macrophages associated to the tumour.
COX-2 expression was associated with ulceration (p=0,005), necrosis (p=0,003), mitotic index (p=0,029), nuclear grade (p=0,035) and degree of pigmentation (p=0,001). Cox-2 expression was observed in tumours with epithelium ulceration, necrosis, high mitotic index and nuclear grade and in less pigmented neoplasms.
3.5. Association of TAMs and COX-2 in canine melanocytic tumours
There was a significant association between the number of TAMs and COX-2 expression in canine melanocytic tumours (p=0,006). Cox2 positive tumours had a high number of TAMs. Among Cox- negative tumours, only 3 out of 18 tumours had a moderate or abundant number of TAMs. Considering only malignant melanomas, in spite of Cox-2 positive tumours had more TAMs than Cox-2 negative tumours, the association was not statistical significant.
|
|
|
||||||
|
|
|
|
|
|
|
||
Histological classification Melanocytoma Melanoma |
8 13 |
0 10 |
0 6 |
|
8 10 |
0 19 |
|
|
Ulceration Absent Present |
15 6 |
1 9 |
0 6 |
|
12 6 |
4 15 |
|
|
Necrosis Absent Present |
18 3 |
6 4 |
0 6 |
|
16 2 |
8 11 |
|
|
Mitotic index I II III |
9 2 10 |
2 1 7 |
10 7 5 |
0,308 | 9 1 8 |
2 3 14 |
|
|
Nuclear grade I II III |
10 2 3 |
3 3 4 |
0 2 4 |
|
10 5 3 |
3 8 8 |
|
|
Degree of pigmentation Scant Moderate Abundant |
0 10 11 |
10 1 1 |
11 2 0 |
|
1 6 11 |
11 6 2 |
|
|
Aberrant cells Absent Present |
19 2 |
7 3 |
2 9 |
|
16 2 |
12 7 |
0,068 | |
Stroma Scarse Moderate Abundant |
3 16 2 |
7 3 0 |
2 0 0 |
|
4 13 1 |
10 8 1 |
0,154 | |
Vascular invasion Absent Present |
19 2 |
8 2 |
2 4 |
|
16 2 |
13 6 |
0,232 |
|
|
|
||||||
|
|
|
|
|
|
|
||
Ulceration Absent Present |
7 6 |
1 9 |
0 6 |
|
4 6 |
4 15 |
0,390 | |
Necrosis Absent Present |
10 3 |
6 4 |
0 6 |
|
8 2 |
8 11 |
0,114 | |
Mitotic index I II III |
1 2 10 |
2 1 7 |
0 1 5 |
0,760 | 1 1 8 |
2 3 14 |
|
|
Nuclear grade I II III |
1 2 10 |
8 3 2 |
3 4 4 |
0,235 | 2 5 3 |
3 8 8 |
0,814 | |
Degree of pigmentation Scant Moderate Abundant |
0 9 4 |
7 1 2 |
5 1 0 |
|
1 5 4 |
11 6 2 |
|
|
Aberrant cells Absent Present |
11 2 |
7 3 |
2 4 |
0,08 | 8 2 |
12 7 |
0,431 | |
Stroma Scarse Moderate Abundant |
3 9 1 |
7 3 0 |
4 2 0 |
0,165 | 4 6 0 |
10 8 1 |
0,555 | |
Vascular invasion Absent Present |
11 2 |
8 2 |
2 4 |
|
8 13 |
2 6 |
0,675 |
4. Discussion
Melanoma is relatively common in dogs, accounting for 3% of all neoplasms and up to 7% of all malignant tumours. Melanocytic neoplasms that arise in the oral cavity, one of the most frequent localization of melanocytic tumours in dog, are virtually always considered malignant and constitute the most common oral malignant neoplasm (Smith et al., 2002). Much work is currently underway in to try and identify specific tumour markers, associated with malignancy. However, more studies are needed to differentiating canine benign from malignant melanocytic neoplasms or predicting survival times.
4.1. TAMs in canine melanocytic tumours
It has long been thought that inflammation and carcinogenesis are related (Le Bitoux&Stamenkovic, 2008). Macrophages belong to the innate immune system and as such constitute one of the first barriers against infection. Depending on the activation state of the macrophage, this antigen presentation may trigger a full-blown active immune response, or may suppress a potential immune reaction (Jager et al., 2011). The role of macrophages in tumour growth and development is complex and multifaceted. Whilst there is limited evidence that TAMs can be directly tumouricidal and stimulate the anti-tumour activity of T cells, there is now contrasting evidence that tumour cells are able to block or evade the activity of TAMs at the tumour site. In some cases, tumour-derived molecules even redirect TAMs activities to promote tumour survival and growth (Bingle et al., 2002).
In our study, TAMs were observed in all tumours analyzed. Melanocytomas presented few macrophages, while malignant melanoma showed generally moderate or intense macrophage infiltration. Higher number of TAMs has been associated with malignancy in different types of human tumours (Siveen&Kuttan, 2009), as breast carcinomas (Leek et al., 1996) and gliomas (Nishie et al., 1999). In human cutaneous melanoma (Torisu et al., 2000), uveal melanoma (Toivonen et al., 2004) and sinonasal melanoma (Shi et al., 2010) a high number of TAMs was closely associated with bad tumour phenotypes. These observations were in accordance with our results in canine melanocytic lesions.
In canine melanocytic tumours, a higher number of TAMs appears associated, in a statistical significant way, with ulceration (p<0,001), necrosis (0,001), nuclear grade (p=0,046), degree of pigmentation (p<0,001), tumoural aberrant cells (p=0,014), stroma (p=0,018) and tumoural embolus (p=0,011). Even considering only malignant melanomas, an association was noted between TMAs and ulceration (p=0,016), histological necrosis (p=0,007), degree of pigmentation (p=<0,001) and presence of vascular invasion by tumoural cells (p=0,049). Interestingly most of these characteristics are classically linked to higher tumoural aggressiveness and poor clinical prognosis in these neoplasias. TAMs could constitute an important marker of canine melanocytic aggressiveness; however, studies with prognostic are needed to clarify this subject.
The statistical significant association observed between tumoural necrosis and a high number of TAMs in malignant melanomas is not surprising. Indeed, in human cancer, evidence has emerged for a symbiotic relationship between tumour cells and TAMs. The pathways involved in this crosstalk could imply a response to micro-environmental factors such as hypoxia, as well as various growth factors and enzymes that stimulate tumour angiogenesis (Bingle et al., 2002). Many macrophage products released in the tumour stroma can directly stimulate the growth of tumour cells and/or promote tumour cell migration and metastasis. These include, for instance, the epidermal growth factor (EGF), cytokines like IL-6 and TNF, as well as chemokines such as CXCL12. TAMs contribute to tumour progression also by producing several factors which enhance neo-angiogenesis and the dissolution and remodeling of the interstitial matrix. Moreover TAMs are a source of potent immunosuppressive molecules, such as IL-10 and PGE2, contributing to the tumour immune-evasion (Allavena et al., 2008; Mantovani et al., 2002; Van Ginderachter et al., 2006). It is probably that similar mechanisms occur also in canine malignant melanomas.
4.2. Cox-2 labeling in canine melanocytic tumours
Cox-2 is a key enzyme controlling the conversion of arachidonic acid to prostaglandin H2, the precursor of various molecules, including prostaglandins, prostacyclins and tromboxanes. Cox-2 is commonly undetectable in normal tissues, but can be induced through several stimuli, including mitogens, growth factors, hormones, and cytokines (Dubois et al., 1998). In recent years, many molecular pathways have been suggested to explain how increased Cox-2 and the resultant prostaglandin overproduction might contribute to carcinogenesis (Hu et al., 2009; Singh-Ranger et al., 2008; Wu&Liou, 2009). These pathways included stimulation of tumoural angiogenesis, decreased tumoural apoptosis, increased invasion and metastasis, immune suppression and tumour associated inflammation (Ghosh et al., 2010). Various studies indicate a link between high Cox-2 expression and malignancy in both human (Balan et al., 2011; Costa et al., 2002; Lee et al., 2011) and canine tumours (Queiroga et al., 2007; Queiroga et al., 2010). In the dog, Cox-2 ‘‘up-regulation’’ has been investigated in different tumours, including prostate (L'Eplattenier et al., 2007), ovarian (Borzacchiello et al., 2007), bladder (Khan et al., 2000), intestinal (McEntee et al., 2002), mammary (Queiroga et al., 2005; Queiroga et al., 2007; Dias Pereira et al., 2009), nasal carcinomas (Impellizeri & Esplin, 2008) and sarcomas, including osteosarcoma and oral fibrosarcoma (Heller et al., 2005; Mullins et al., 2004). In human cancer, Cox-2 expression has been detected in a considerable number of epithelial tumours as breast, lung, colon, prostate, head and neck, gastric, ovary, among many others (Ghosh et al., 2010; Menczer, 2009; Wu et al., 2010).
Concerning malignant melanoma, in humans it was recently reported that changes in Cox-2 expression levels were correlated with development and progression of human melanoma (Goulet et al., 2003; Kuzbicki et al., 2006). COX-2 expression arises as a potential immunohistochemical marker for distinguishing human cutaneous melanomas from benign melanocytic lesions (Minami et al., 2011; Pires et al., 2010). Additionally, Cox-2 expression appears as a useful prognostic marker being related with histological and clinical malignant melanoma aggressiveness (Becker et al., 2009).
In canine melanocytic tumours, Cox-2 expression was recently described (Paglia et al., 2009; Pires et al., 2010). Cox-2 over-expression was related with a tumoural malignant behavior (Pires et al., 2010) and with a poor overall survival (Martínez et al., 2011). In the present work, Cox-2 expression was associated with ulceration (p=0,005), necrosis (p=0,003), mitotic index (p=0,029), nuclear grade (p=0,035) and degree of pigmentation (p=0,001). These associations could represent the higher aggressiveness of Cox-2 positive melanocytic tumours. Curiously, these associations lost their statistical significance when we consider for statistical analysis only the group of malignant melanomas. However, an association with mitotic index is observed, that suggests that Cox-2 is associated with a higher cellular proliferation. The real significance of these results needs to be clarified. Clinical studies, with follow-up information and proliferation markers will be necessary to clarify if Cox-2 could be more important in early phases of carcinogenesis or also in tumour progression.
4.3. Relationship between TAMs and Cox-2 expression in canine melanocytic tumours
Tumour associated macrophages and high COX-2 expression have been both associated with malignancy in canine melanocytic tumours, but their potential interdependence has not yet been evaluated. The present study showed that there is a close relationship between TAMs and Cox-2 expression in canine melanocytic lesions. This is the first time, to our best knowledge, that a similar relationship was investigated in tumours of domestic animals. This crosstalk is referred in human tumours, as colorectal carcinoma (Naghshvar et al., 2009), urotelial carcinoma (Chen et al., 2009), basal cell carcinoma (Tjiu et al., 2009) and in breast cancer cells (Hou et al., 2011). The pathways involved in this relationship are diverse, and remain to be completed elucidated. In human basal cell carcinoma, macrophages induced COX-2-dependent release of matrix metalloproteinase-9 and subsequent increased invasion and induced COX-2-dependent secretion of basic fibroblast growth factor and vascular endothelial growth factor-A, and increased angiogenesis (Tjiu et al., 2009). Macrophage-mediated induction of COX-2 in breast cancer cells is a consequence of IL-1β-mediated stimulation of ROS→Src→MAP kinase→AP-1 signaling. IL-1β-dependent induction of COX-2 in breast cancer cells provides a mechanism whereby macrophages contribute to tumour progression (Hou et al., 2011). Another mechanism proposed could involve Cox-2 induced angiogenesis through increasing TAM infiltration or hypoxia-inducible factor-1alpha by hypoxia (Chen et al., 2009).
Considering only malignant melanomas, the association was not significant that could suggested that this cross-talk (between TAMs and Cox-2 positive tumoural cells) could be decisive in carcinogenesis but not in tumour progression. Only more studies could help to investigate the meaning of these findings. In turn, in human oral squamous cell carcinoma, Cox-2 and TAMs are not related (Boas et al., 2010).
The development of therapeutic targeting of cancer promoting inflammatory reactions is crucially dependent on defining the underlying cellular and molecular mechanisms in relevant systems (Allavena et al., 2008). By inhibiting the release of prostaglandins from the tumour and by blocking COX activity in immune effector cells, NSAIDs may also bias the function of immune cells towards a more tumouricidal phenotype (Lang et al., 2006).
5. Conclusion
In conclusion, this study presents a close relationship of TAM and Cox-2 expression in canine melanocytic lesions. It is possible that proinflammatory cytokines released by intratumoural macrophages, up-regulate Cox-2 tumour cells expression stimulating tumour progression. Additionally, the differences observed between benign and malignant melanocytic lesions may suggest that TAM and Cox-2 are implicated in the progression of melanocytic precursor lesions to malignant melanoma.
References
- 1.
Allavena P. Sica A. Solinas G. Porta C. Mantovani A. 2008 The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. ,66 1 (April 2008),1 9 ,1040-8428 - 2.
Balan R. Amalinei C. Giusca S. E. Ditescu D. Gheorghita V. Crauciuc E. Caruntu I. D. 2011 Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions. ,52 1 2011),39 43 ,1220-0522 - 3.
Becker M. R. Siegelin M. D. Rompel R. Enk A. H. Gaiser T. 2009 COX-2 expression in malignant melanoma: a novel prognostic marker? ,19 1 (February 2009),8 16 ,1473-5636 - 4.
Bergman P. J. Camps-Palau M. A. Mc Knight J. A. Leibman N. F. Craft D. M. Leung C. Liao J. Riviere I. Sadelain M. Hohenhaus A. E. Gregor P. Houghton A. N. Perales M. A. Wolchok J. D. 2006 Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. ,24 21 (May 22 2006),4582 4585 ,0026-4410 X - 5.
Berkelhammer J. Hook R. R. Jr 1980 Growth of Sinclair swine melanoma in the hamster cheek pouch. ,29 3 (March 1980),193 195 ,0041-1337 - 6.
Bianchini F. Massi D. Marconi C. Franchi A. Baroni G. Santucci M. Mannini A. Mugnai G. Calorini L. 2007 Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. ,83 4 (June 2007),320 328 , - 7.
Bingle L. Brown N. J. Lewis C. E. 2002 The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. ,196 3 (March 2002),254 265 ,0022-3417 - 8.
Boas D. S. Takiya C. M. Coelho-Sampaio T. L. Moncao-Ribeiro L. C. Ramos E. A. Cabral M. G.&dos Santos. J. N. 2010 Immunohistochemical detection of Ki-67 is not associated with tumor-infiltrating macrophages and cyclooxygenase-2 in oral squamous cell carcinoma. ,39 7 (August 2010),565 570 ,1600-0714 - 9.
Bolon B. Calderwood Mays. M. B. Hall B. J. 1990 Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. ,27 2 (March 1990),96 102 ,0300-9858 - 10.
Borzacchiello G. Russo V. Russo M. 2007 Immunohistochemical expression of cyclooxygenase-2 in canine ovarian carcinomas. ,54 5 (Jun 2007),247 249 ,1439-0442 - 11.
Brocker E. B. Zwadlo G. Suter L. Brune M. Sorg C. 1987 Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. ,25 2 1987),81 86 , - 12.
Cerella C. Sobolewski C. Dicato M. Diederich M. 2010 Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. ,80 12 (December 15 2010),1801 1815 , - 13.
Chen W. T. Hung W. C. Kang W. Y. Huang Y. C. Su Y. C. Yang C. H. Chai C. Y. 2009 Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1alpha expression, and tumor angiogenesis. ,117 3 (March 2009),176 184 ,1600-0463 - 14.
Chwirot B. W. Kuzbicki L. 2007 Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. ,17 3 (June 2007),139 145 , - 15.
Conroy J. D. 1967 Melanocytic tumors of domestic animals with special reference to dogs. ,96 4 (October 1967),372 380 ,0000-3987 X - 16.
Conroy J. D. 1967 Melanocytic tumors of domestic animals with special reference to dogs. ,96 4 (October 1967),372 380 ,0000-3987 X - 17.
Costa C. Soares R. Reis-Filho J. S. Leitao D. Amendoeira I. Schmitt F. C. 2002 Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. ,55 6 (June 2002),429 434 ,0021-9746 - 18.
Dias Pereira. P. Lopes C. C. Matos A. J. Santos M. Gartner F. Medeiros R. Lopes C. 2009 COX-2 Expression in Canine Normal and Neoplastic Mammary Gland. ogy,140 4 (May 2009), - 19.
Dorn C. R. Priester W. A. 1976 Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. ,169 11 (December 1 1976),1202 1206 ,0003-1488 - 20.
Dubois R. N. Abramson S. B. Crofford L. Gupta R. A. Simon L. S. Van De Putte L. B. Lipsky P. E. 1998 Cyclooxygenase in biology and disease. ,12 12 (September 1998),1063 1073 , - 21.
Ghosh N. Chaki R. Mandal V. Mandal S. C. 2010 COX-2 as a target for cancer chemotherapy. ,62 2 (March-April 2010),233 244 ,1734-1140 - 22.
Goldschmidt M. Dunstan R. Stannard A. 1998 Armed Forces Institute of Pathology, American Registry of Pathology, Washington D.C. - 23.
Goldschmidt M. H. 1985 Benign and malignant melanocytic neoplasms of domestic animals. ,7 Suppl,1985 ,203 212 ,0193-1091 - 24.
Goulet A. C. Einsphar J. G. Alberts D. S. Beas A. Burk C. Bhattacharyya A. Bangert J. Harmon J. M. Fujiwara H. Koki A. Nelson M. A. 2003 Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. ,2 6 (November-December 2003),713 718 , - 25.
Heller D. A. Clifford C. A. Goldschmidt M. H. Holt D. E. Manfredi M. J. Sorenmo K. U. 2005 Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. ,42 3 (May 2005),350 353 , - 26.
Hook R. R. Jr Berkelhammer J. Oxenhandler R. W. 1982 Melanoma: Sinclair swine melanoma. ,108 1 (July 1982),130 133 ,0002-9440 - 27.
Hou Z. Falcone D. J. Subbaramaiah K. Dannenberg A. J. 2011 Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1{beta} auto-amplification. , [Epub ahead of print] (February 10 2011),1460-2180 1460 2180 - 28.
Hu M. Peluffo G. Chen H. Gelman R. Schnitt S. Polyak K. 2009 Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. ,106 9 (March 3 2009),3372 3377 ,1091-6490 - 29.
Hussein M. R. Al-Assiri M. Musalam A. O. 2009 Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. ,86 2 (April 2009),108 113 , - 30.
Impellizeri J. A. Esplin D. G. 2008 Expression of cyclooxygenase-2 in canine nasal carcinomas. ,176 3 (June 2008),408 410 , - 31.
Jager M. J. Ly L. V. El Filali M. Madigan M. C. 2011 Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? ,30 2 (March 2011),129 146 ,1873-1635 - 32.
Johnson P. J. 1998 Dermatologic tumors (excluding sarcoids). ,14 3 (December 1998),625 658 ,0749-0739 - 33.
Khan K. N. Knapp D. W. Denicola D. B. Harris R. K. 2000 Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. ,61 5 (May 2000),478 481 , - 34.
Kuzbicki L. Sarnecka A. Chwirot B. W. 2006 Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. ,16 1 (February 2006),29 36 , - 35.
L’Eplattenier H. F. Lai C. L. van den Ham. R. Mol J. van Sluijs F. Teske E. 2007 Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. ,21 4 (July-August 2007),776 782 , - 36.
Lang S. Picu A. Hofmann T. Andratschke M. Mack B. Moosmann A. Gires O. Tiwari S. Zeidler R. 2006 COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors. ,19 2 (April-June 2006),409 419 ,0394-6320 - 37.
Laprie C. Abadie J. Amardeilh M. F. Net J. L. Lagadic M. Delverdier M. 2001 MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. ,12 3 (June 2001),139 147 ,0959-4493 - 38.
Le Bitoux M. A. Stamenkovic I. 2008 Tumor-host interactions: the role of inflammation. ,130 6 (December 2008),1079 1090 ,0948-6143 - 39.
Lee C. H. Roh J. W. Choi J. S. Kang S. Park I. A. Chung H. H. Jeon Y. T. Kim J. W. Park N. H. Kang S. B. Song Y. S. 2011 Cyclooxygenase-2 Is an Independent Predictor of Poor Prognosis in Uterine Leiomyosarcomas. , Vol. No. (March 15 2011),1525-1438 1525 1438 - 40.
Leek R. D. Lewis C. E. Whitehouse R. Greenall M. Clarke J. Harris A. L. 1996 Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. ,56 20 (October 15 1996),4625 4629 ,0008-5472 - 41.
Mantovani A. Sozzani S. Locati M. Allavena P. Sica A. 2002 Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. ,23 11 (November 2002),549 555 ,1471-4906 - 42.
Marino D. J. Matthiesen D. T. Stefanacci J. D. Moroff S. D. 1995 Evaluation of dogs with digit masses: 117 cases (1981-1991). ,207 6 (September 15 1995),726 728 ,0003-1488 - 43.
Martínez C. M. Dr-Verdú Peñafiel. Vilafranca C. Ramírez M. Méndez-Gallego G. Buendí M. A. A. J. J. S. 2011 Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms. , Vol. February 3. [Epub ahead of print],2011 , - 44.
Mc Entee M. F. Cates J. M. Neilsen N. 2002 Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. ,39 4 (July 2002),428 436 , - 45.
Menczer J. 2009 Cox-2 expression in ovarian malignancies: a review of the clinical aspects. ,146 2 (October 2009),129 132 ,1872-7654 - 46.
Minami S. Lum C. A. Kitagawa K. M. Namiki T. S. 2011 Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions. ,50 1 (January 2011),24 29 ,0011-9059 - 47.
Misfeldt M. L. Grimm D. R. 1994 Sinclair miniature swine: an animal model of human melanoma. ,43 1-3 , (October 1994),167 175 ,0165-2427 - 48.
Mohammed S. I. Khan K. N. Sellers R. S. Hayek M. G. De Nicola D. B. Wu L. Bonney P. L. Knapp D. W. 2004 Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. ,70 5 (May 2004),479 483 , - 49.
Mukaratirwa S. Chikafa L. Dliwayo R. Moyo N. 2006 Mast cells and angiogenesis in canine melanomas: malignancy and clinicopathological factors. ,17 2 (April 2006),141 146 ,0959-4493 - 50.
Mulligan R. M. 1961 Melanoblastic tumors in the dog. ,22 No. (May 1961),345 351 ,0002-9645 - 51.
Mullins M. N. Lana S. E. Dernell W. S. Ogilvie G. K. Withrow S. J. Ehrhart E. J. 2004 Cyclooxygenase-2 expression in canine appendicular osteosarcomas. ,18 6 (November-December 2004),859 865 , - 52.
Naghshvar F. Torabizadeh Z. Emadian O. Enami K. Ghahremani M. 2009 Correlation of cyclooxygenase 2 expression and inflammatory cells infiltration in colorectal cancer. ,12 1 (January 1 2009),98 100 ,1028-8880 - 53.
Nishie A. Ono M. Shono T. Fukushi J. Otsubo M. Onoue H. Ito Y. Inamura T. Ikezaki K. Fukui M. Iwaki T. Kuwano M. 1999 Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. ,5 5 (May 1999),1107 1113 ,1078-0432 - 54.
Paglia D. Dubielzig R. R. Kado-Fong H. K. Maggs D. J. 2009 Expression of cyclooxygenase-2 in canine uveal melanocytic neoplasms. ,70 10 (October 2009),1284 1290 ,0002-9645 - 55.
Piras F. Colombari R. Minerba L. Murtas D. Floris C. Maxia C. Corbu A. Perra M. T. Sirigu P. 2005 The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. ,104 6 (September 15 2005),1246 1254 , - 56.
Pires I. Garcia A. Prada J. Queiroga F. L. 2010 COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours. ,143 2-3 , (August-October 2010),142 149 ,1532-3129 - 57.
Queiroga F. L. Alves A. Pires I. Lopes C. 2007 Expression of Cox-1 and Cox-2 in canine mammary tumours. ,136 2-3 , (February-April 2007),177 185 , - 58.
Queiroga F. L. Perez-Alenza M. D. Silvan G. Pena L. Lopes C. Illera J. C. 2005 Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. ,25 6B (November-December 2005),4269 4275 ,0250-7005 - 59.
Queiroga F. L. Pires I. Parente M. Gregorio H. Lopes C. S. 2010 COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. , Vol. No. (July 30 2010),1532-2971 1532 2971 - 60.
Ramos-Vara J. A. Beissenherz M. E. Miller M. A. Johnson G. C. Pace L. W. Fard A. Kottler S. J. 2000 Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. ,37 6 (November 2000),597 608 ,0300-9858 - 61.
Roels S. Tilmant K. Ducatelle R. 1999 PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. ,121 1 (July 1999),13 24 ,0021-9975 - 62.
Roels S. Tilmant K. Ducatelle R. 2001 p53 expression and apoptosis in melanomas of dogs and cats. ,70 1 (February 2001),19 25 ,0034-5288 - 63.
Shi L. Lei D. Ma C. Xu F. Li Y. Wang Y. Cong N. Liu D. Pan X. L. 2010 Clinicopathological Implications of Tumour-associated Macrophages and Vascularization in Sinonasal Melanoma. ,38 4 (July-August 2010),1276 1286 ,0300-0605 - 64.
Singh-Ranger G. Salhab M. Mokbel K. 2008 The role of cyclooxygenase-2 in breast cancer: review. ,109 2 (May 2008),189 198 ,0167-6806 - 65.
Siveen K. S. Kuttan G. 2009 Role of macrophages in tumour progression. ,123 2 (April 27 2009),97 102 ,1879-0542 - 66.
Smith S. H. Goldschmidt M. H. Mc Manus P. M. 2002 A comparative review of melanocytic neoplasms. ,39 6 (November 2002),651 678 ,0300-9858 - 67.
Spangler W. L. Kass P. H. 2006 The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. ,43 2 (March 2006),136 149 ,0300-9858 - 68.
Taylor K. H. Smith A. N. Higginbotham M. Schwartz D. D. Carpenter D. M. Whitley E. M. 2007 Expression of vascular endothelial growth factor in canine oral malignant melanoma. ,5 4 (December 2007),208 218 ,1476-5829 - 69.
Tjiu J. W. Chen J. S. Shun C. T. Lin S. J. Liao Y. H. Chu C. Y. Tsai T. F. Chiu H. C. Dai Y. S. Inoue H. Yang P. C. Kuo M. L. Jee S. H. 2009 Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. ,129 4 (April 2009),1016 1025 ,1523-1747 - 70.
Toivonen P. Makitie T. Kujala E. Kivela T. 2004 Microcirculation and tumor-infiltrating macrophages choroidal and ciliary body melanoma and corresponding metastases. ,45 1 (January 2004),1 6 ,0146-0404 - 71.
Torisu H. Ono M. Kiryu H. Furue M. Ohmoto Y. Nakayama J. Nishioka Y. Sone S. Kuwano M. 2000 Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNF alpha and IL-1 alpha. ,85 2 (January 15 2000),182 188 ,0020-7136 - 72.
Valentine B. A. 1995 Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991). ,9 5 (September-October 1995),291 297 ,0891-6640 - 73.
Van Ginderachter J. A. Movahedi K. Hassanzadeh Ghassabeh. G. Meerschaut S. Beschin A. Raes G. De Baetselier P. 2006 Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. ,211 6-8 , 2006),487 501 ,0171-2985 - 74.
von Euler. H. Sadeghi A. Carlsson B. Rivera P. Loskog A. Segall T. Korsgren O. Totterman T. H. 2008 Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. ,31 4 (May 2008),377 384 ,1524-9557 - 75.
Wu K. K. Liou J. Y. 2009 Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta--> 14-3-3epsilon pathway. ,512 2009 ,295 307 ,1064-3745 - 76.
Wu R. Abramson A. L. Symons M. H. Steinberg B. M. 2010 Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. ,127 9 (November 1 2010),2230 2237 ,1097-0215